Iclusig PMS in CML or Ph+ALL Patients
This is a Post-Marketing Surveillance (PMS) of Iclusig速 Tablets in accordance with Korean regulations on Risk Management Plan (RMP). This PMS is to assess safety and effectiveness data after administrating Ponatinib (of Iclusig速 Tablets) per approved indication, usage and dosage.
Chronic Myeloid Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
DRUG: Ponatinib
The incidence rate and the number of Adverse Events (AE)/Adverse Drug Reactions (ADR), Serious AE/ADR, Unexpected AE/ADR, until 14 days after last administration
The number of subjects who satisfy CHR, at 3 months and 6 months from administration|The percentage of subjects who satisfy CHR, at 3 months and 6 months from administration|The number of subjects who satisfy MCyR, at 3 months and 6 months from administration|The percentage of subjects who satisfy MCyR, at 3 months and 6 months from administration|The number of subjects who satisfy MMR, at 3 months and 6 months from administration|The percentage of subjects who satisfy MMR, at 3 months and 6 months from administration
This is a Post-Marketing Surveillance (PMS) of Iclusig速 Tablets in accordance with Korean regulations on Risk Management Plan (RMP). This PMS is to assess safety and effectiveness data after administrating Ponatinib (of Iclusig速 Tablets) per approved indication, usage and dosage.